Abstract:It has been reported that advanced glycation end-products (AGEs) enhance calcification in cultured rat aortic vascular smooth muscle cells (VSMCs) by up-regulation RAGE. The present study investigated whether rosiglitazone, antidiabetic agents clinically used to treat patients with type 2 diabetes, might modulate RAGE expression, thus attenuating an osteogenic response induced by AGE–bovine serum albumin (AGE–BSA) in cultured VSMCs. Stimulation of VSMCs with rosiglitazone decreased AGEs-dependent changes in calcium accumulation. This effect was caused by an inhibition of AGEs-induced RAGE mRNA and protein expression. Mechanistic studies revealed that these effects on RAGE expression were caused by an inhibition of AGEs-induced nuclear factor-κB (NF-κB) protein expression. The functional relevance of reduced RAGE expression was demonstrated by showing that pretreatment of VSMCs with rosiglitazone decreased AGEs-induced tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) mRNA expression. In conclusion, rosiglitazone reduces RAGE expression in VSMCs, thus limiting the cells' susceptibility toward proinflammatory AGE effects, then attenuating vascular calcification in diabetes.

Rosiglitazone improved advanced glycation end products-induced calcification in vitro by suppressing receptor for AGEs expression